Do analysts rate KOD or INDP?

Kodiak Sciences currently has a consensus target price of $53.67, indicating a potential upside of 70.26%. Given Kodiak Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Kodiak Sciences is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, KOD or INDP?

Kodiak Sciences is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.19 N/A Indaptus Therapeutics N/A N/A -$20.85M -$6.33 N/A

Is KOD or INDP more profitable?

Kodiak Sciences' return on equity of -273.23% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -273.23% -85.48% Indaptus Therapeutics N/A -302.89% -203.49%

Do analysts prefer AGIO or INDP?

Agios Pharmaceuticals currently has a consensus price target of $41.75, indicating a potential upside of 22.11%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Agios Pharmaceuticals is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.55 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate NKTR or INDP?

Nektar Therapeutics presently has a consensus target price of $138.50, indicating a potential upside of 140.20%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nektar Therapeutics 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.77 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer MESO or INDP?

Mesoblast currently has a consensus target price of $39.00, suggesting a potential upside of 155.07%. Given Mesoblast's stronger consensus rating and higher possible upside, equities analysts clearly believe Mesoblast is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MESO or INDP more profitable?

Mesoblast's return on equity of 0.00% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Indaptus Therapeutics N/A -302.89% -203.49%

Do analysts rate VCEL or INDP?

Vericel currently has a consensus target price of $58.40, indicating a potential upside of 50.55%. Given Vericel's stronger consensus rating and higher probable upside, equities analysts clearly believe Vericel is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Indaptus Therapeutics (INDP) Competitors

$3.77 -0.22 (-5.51%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.90 +0.13 (+3.45%)

As of 07:42 AM Eastern

Compare

INDP vs. KOD, AGIO, NKTR, MESO, and VCEL

Should you buy Indaptus Therapeutics stock or one of its competitors? Indaptus Therapeutics's main competitors and comparable companies include Kodiak Sciences (KOD), Agios Pharmaceuticals (AGIO), Nektar Therapeutics (NKTR), Mesoblast (MESO), and Vericel (VCEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Indaptus Therapeutics compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Indaptus Therapeutics (NASDAQ:INDP) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Kodiak Sciences has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

Kodiak Sciences' return on equity of -273.23% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-273.23%	-85.48%
Indaptus Therapeutics	N/A	-302.89%	-203.49%

In the previous week, Kodiak Sciences had 7 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 7 mentions for Kodiak Sciences and 0 mentions for Indaptus Therapeutics. Kodiak Sciences' average media sentiment score of 0.27 beat Indaptus Therapeutics' score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Kodiak Sciences	Neutral
Indaptus Therapeutics	Neutral

Kodiak Sciences currently has a consensus target price of $53.67, indicating a potential upside of 70.26%. Given Kodiak Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Kodiak Sciences is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kodiak Sciences is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

Summary

Kodiak Sciences beats Indaptus Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Indaptus Therapeutics (NASDAQ:INDP) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Agios Pharmaceuticals has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

Indaptus Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Indaptus Therapeutics	N/A	-302.89%	-203.49%

Agios Pharmaceuticals currently has a consensus price target of $41.75, indicating a potential upside of 22.11%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Agios Pharmaceuticals is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Indaptus Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	37.78	-$412.78M	-$7.01	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

7.1% of Indaptus Therapeutics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Agios Pharmaceuticals had 17 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 0 mentions for Indaptus Therapeutics. Agios Pharmaceuticals' average media sentiment score of 0.83 beat Indaptus Therapeutics' score of 0.00 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Agios Pharmaceuticals	Positive
Indaptus Therapeutics	Neutral

Summary

Agios Pharmaceuticals beats Indaptus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Indaptus Therapeutics (NASDAQ:INDP) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Nektar Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

In the previous week, Nektar Therapeutics had 9 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 9 mentions for Nektar Therapeutics and 0 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.00 beat Nektar Therapeutics' score of -0.05 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nektar Therapeutics	Neutral
Indaptus Therapeutics	Neutral

Nektar Therapeutics presently has a consensus target price of $138.50, indicating a potential upside of 140.20%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Indaptus Therapeutics has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	35.64	-$164.08M	-$6.70	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Indaptus Therapeutics has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-287.84%	-37.87%	-25.67%
Indaptus Therapeutics	N/A	-302.89%	-203.49%

Summary

Nektar Therapeutics beats Indaptus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and Indaptus Therapeutics (NASDAQ:INDP) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Mesoblast's return on equity of 0.00% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Indaptus Therapeutics	N/A	-302.89%	-203.49%

In the previous week, Mesoblast had 5 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 5 mentions for Mesoblast and 0 mentions for Indaptus Therapeutics. Mesoblast's average media sentiment score of 0.83 beat Indaptus Therapeutics' score of 0.00 indicating that Mesoblast is being referred to more favorably in the media.

Company	Overall Sentiment
Mesoblast	Positive
Indaptus Therapeutics	Neutral

Mesoblast currently has a consensus target price of $39.00, suggesting a potential upside of 155.07%. Given Mesoblast's stronger consensus rating and higher possible upside, equities analysts clearly believe Mesoblast is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mesoblast has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

Indaptus Therapeutics has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$120.25M	16.51	-$57.50M	-$0.28	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Mesoblast beats Indaptus Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Vericel?

Vericel (NASDAQ:VCEL) and Indaptus Therapeutics (NASDAQ:INDP) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

In the previous week, Vericel had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 1 mentions for Vericel and 0 mentions for Indaptus Therapeutics. Vericel's average media sentiment score of 1.73 beat Indaptus Therapeutics' score of 0.00 indicating that Vericel is being referred to more favorably in the media.

Company	Overall Sentiment
Vericel	Very Positive
Indaptus Therapeutics	Neutral

Vericel has higher revenue and earnings than Indaptus Therapeutics. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	7.19	$16.52M	$0.47	82.53
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

7.1% of Indaptus Therapeutics shares are owned by institutional investors. 7.6% of Vericel shares are owned by insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vericel has a net margin of 7.91% compared to Indaptus Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.91% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Indaptus Therapeutics	N/A	-302.89%	-203.49%

Vericel has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

Vericel currently has a consensus target price of $58.40, indicating a potential upside of 50.55%. Given Vericel's stronger consensus rating and higher probable upside, equities analysts clearly believe Vericel is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Vericel beats Indaptus Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Indaptus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDP vs. The Competition

Export

Metric	Indaptus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$531.64M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.60	13.88	274.06	25.69
Price / Sales	N/A	1,343.72	637.81	78.88
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	2.69	15.21	10.40	6.32
Net Income	-$20.85M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-4.07%	-1.72%	-0.69%	0.17%
1 Month Performance	225.00%	-6.17%	-3.18%	-3.27%
1 Year Performance	27.36%	30.66%	15.13%	5.58%

Indaptus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDP Indaptus Therapeutics	0.2026 of 5 stars	$3.77 -5.5%	N/A	+21.2%	$531.64M	N/A	N/A	5
KOD Kodiak Sciences	2.1431 of 5 stars	$31.52 -6.7%	$53.67 +70.3%	+129.7%	$2.12B	N/A	N/A	124	News Coverage
AGIO Agios Pharmaceuticals	3.33 of 5 stars	$34.19 -2.2%	$41.75 +22.1%	-9.7%	$2.09B	$54.03M	N/A	540	Positive News Analyst Forecast Analyst Revision
NKTR Nektar Therapeutics	2.6452 of 5 stars	$57.66 -5.4%	$138.50 +140.2%	-3.3%	$2.08B	$55.23M	N/A	63	Analyst Forecast
MESO Mesoblast	2.2633 of 5 stars	$15.29 -4.0%	$39.00 +155.1%	-6.3%	$2.07B	$120.25M	N/A	108	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDP) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indaptus Therapeutics (INDP) Competitors

INDP vs. KOD, AGIO, NKTR, MESO, and VCEL

How does Indaptus Therapeutics compare to Kodiak Sciences?

Summary

How does Indaptus Therapeutics compare to Agios Pharmaceuticals?

Summary

How does Indaptus Therapeutics compare to Nektar Therapeutics?

Summary

How does Indaptus Therapeutics compare to Mesoblast?

Summary

How does Indaptus Therapeutics compare to Vericel?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indaptus Therapeutics (INDP) Competitors

INDP vs. KOD, AGIO, NKTR, MESO, and VCEL

How does Indaptus Therapeutics compare to Kodiak Sciences?

Do insiders and institutionals believe in KOD or INDP?

Which has more volatility and risk, KOD or INDP?

Is KOD or INDP more profitable?

Does the media refer more to KOD or INDP?

Do analysts rate KOD or INDP?

Which has higher valuation & earnings, KOD or INDP?

Summary

How does Indaptus Therapeutics compare to Agios Pharmaceuticals?

Which has more volatility & risk, AGIO or INDP?

Is AGIO or INDP more profitable?

Do analysts prefer AGIO or INDP?

Which has better earnings & valuation, AGIO or INDP?

Do insiders & institutionals have more ownership in AGIO or INDP?

Does the media refer more to AGIO or INDP?

Summary

How does Indaptus Therapeutics compare to Nektar Therapeutics?

Which has more volatility & risk, NKTR or INDP?

Does the media favor NKTR or INDP?

Do analysts rate NKTR or INDP?

Which has higher earnings and valuation, NKTR or INDP?

Do insiders and institutionals have more ownership in NKTR or INDP?

Is NKTR or INDP more profitable?

Summary

How does Indaptus Therapeutics compare to Mesoblast?

Is MESO or INDP more profitable?

Does the media favor MESO or INDP?

Do analysts prefer MESO or INDP?

Which has more volatility and risk, MESO or INDP?

Which has stronger valuation & earnings, MESO or INDP?

Do insiders and institutionals hold more shares of MESO or INDP?

Summary

How does Indaptus Therapeutics compare to Vericel?

Does the media favor VCEL or INDP?

Which has better earnings and valuation, VCEL or INDP?

Do institutionals and insiders believe in VCEL or INDP?

Is VCEL or INDP more profitable?

Which has more volatility and risk, VCEL or INDP?

Do analysts rate VCEL or INDP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools